| (Values in U.S. Thousands) | Apr, 2025 | Apr, 2024 | Apr, 2023 | Apr, 2022 | Apr, 2021 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -3,140 | -1,561 | -5,661 | -6,655 | -4,976 |
| Net Income Growth | -101.09% | +72.42% | +14.93% | -33.73% | -330.52% |
Izotropic Corp (IZO.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Izotropic Corp is a research and development company specializing in cancer research and early detection for breast cancer. It is engaged in advancing breast cancer imaging through the commercialization of medical imaging technologies. The company's current focus is on the commercialization of its first medical imaging device, IzoView, a dedicated Breast CT Imaging System, developed to provide high resolution, true 3D volumetric visualization of the breast without compression for breast cancer detection and diagnosis.
Fiscal Year End Date: 04/30